TY - JOUR
T1 - Breast cancer and the renin-angiotensin system (RAS)
T2 - Therapeutic approaches and related metabolic diseases
AU - de Miranda, Flávia Sardela
AU - Guimarães, João Pedro Tôrres
AU - Menikdiwela, Kalhara R.
AU - Mabry, Brennan
AU - Dhakal, Rabin
AU - Rahman, Rakhshanda layeequr
AU - Moussa, Hanna
AU - Moustaid-Moussa, Naima
N1 - Funding Information:
This review was supported in part by a Susan G. Komen® Breast Cancer Challenge Award, sponsored by The Obesity Society.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/5/15
Y1 - 2021/5/15
N2 - The Renin-Angiotensin System (RAS) is classically recognized for regulating blood pressure and fluid balance. Recently, this role has extended to other areas including inflammation, obesity, diabetes, as well as breast cancer. RAS components are expressed in normal and cancerous breast tissues, and downregulation of RAS inhibits metastasis, proliferation, angiogenesis, and desmoplasia in the tumor microenvironment. Therefore, RAS inhibitors (Angiotensin receptor blockers, ARBs, or angiotensin converting enzyme inhibitors, ACE-I) may be beneficial as preventive adjuvant therapies to thwart breast cancer development and improve outcomes, respectively. Given the beneficial effects of RAS inhibitors in metabolic diseases, which often co-exist in breast cancer patients, combining RAS inhibitors with other breast cancer therapies may enhance the effectiveness of current treatments. This review scrutinizes above associations, to advance our understanding of the role of RAS in breast cancer and its potential for repurposing of RAS inhibitors to improve the therapeutic approach for breast cancer patients.
AB - The Renin-Angiotensin System (RAS) is classically recognized for regulating blood pressure and fluid balance. Recently, this role has extended to other areas including inflammation, obesity, diabetes, as well as breast cancer. RAS components are expressed in normal and cancerous breast tissues, and downregulation of RAS inhibits metastasis, proliferation, angiogenesis, and desmoplasia in the tumor microenvironment. Therefore, RAS inhibitors (Angiotensin receptor blockers, ARBs, or angiotensin converting enzyme inhibitors, ACE-I) may be beneficial as preventive adjuvant therapies to thwart breast cancer development and improve outcomes, respectively. Given the beneficial effects of RAS inhibitors in metabolic diseases, which often co-exist in breast cancer patients, combining RAS inhibitors with other breast cancer therapies may enhance the effectiveness of current treatments. This review scrutinizes above associations, to advance our understanding of the role of RAS in breast cancer and its potential for repurposing of RAS inhibitors to improve the therapeutic approach for breast cancer patients.
KW - Breast cancer
KW - Cancer therapy
KW - Renin-angiotensin system
UR - http://www.scopus.com/inward/record.url?scp=85104942599&partnerID=8YFLogxK
U2 - 10.1016/j.mce.2021.111245
DO - 10.1016/j.mce.2021.111245
M3 - Article
AN - SCOPUS:85104942599
SN - 0303-7207
VL - 528
JO - Molecular and Cellular Endocrinology
JF - Molecular and Cellular Endocrinology
M1 - 111245
ER -